Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2016 | comment | Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2016
Autor:
Dr. Ercan Müldür

Summary

The incidence of prostate cancer is strongly correlated with age, with 35 % of patients aged 65–74 years and 25 % aged 75 years or older being affected [1]. Prostate cancer is third leading cause of cancer death among men aged 80 years and older. Of patients dying of prostate cancer, 41 % are aged 75–84 years, and 30 % above 85 years [2]. Fortunately treatment for metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the last few years.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe